Clinical Trial Update: A Multi-center, Non-interventional, Prospective Study of Durvalumab in Unresectable Locally Advanced NSCLC in Routine Clinical Practice in Russia

View source ↗

Summary

A multi-center, non-interventional prospective study evaluating durvalumab in unresectable locally advanced non-small cell lung cancer in routine clinical pract…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: NSCLC, Non-small-cell Lung Carcinoma | Status: ACTIVE_NOT_RECRUITING